DarioHealth Preps for New iPhone
Agility to Navigate Complex Mobile Ecosystem Showcases DarioHealth's Versatility
Sep 8, 2016
BOSTON, Sept. 8, 2016 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), developer of the Dario™ Blood Glucose Monitoring System, today announced that it is adapting its flagship product to also incorporate use with the new Apple® iPhone® 7. After receiving regulatory clearance for marketing by the U.S. Food and Drug Administration and other applicable regulatory agencies in Canada, Europe and Australia, customers will be able to select which DarioHealth product they require for connection to their smartphone.
The long-standing rumor that Apple's new iPhone 7 would come without a traditional headphone jack in favor of their Lightning® connector was confirmed by Apple, leaving out many products that depend on the headphone jack for connectivity. The Dario™ Blood Glucose Monitoring System, which launched a direct-to-consumer model earlier in the year, relies on connecting its proprietary meter to a smartphone via the headphone jack.
"This news comes as no surprise to us, and we've been working on a solution for quite some time now," said Erez Raphael, DarioHealth's Chief Executive Officer. "Our team's agility to navigate the complex mobile ecosystem showcases DarioHealth's versatility and passion to be at the forefront of cutting-edge technology in general, and the diabetes healthcare market specifically."
There is no timeframe when the new Dario™ Blood Glucose Monitoring System, compatible for use with the iPhone 7, will be commercially available; however, Mr. Raphael confirmed that the footprint and packaging for the product would be the same.
Mr. Raphael concluded, "The Dario™ Blood Glucose Monitoring System has received rave reviews from our users, and we are committed to providing an accurate, extraordinary product that can be discreetly tucked away in a backpack, pocket, or purse. This is important to our users and therefore, the updated meter compatible with the iPhone 7 will be the same size as our current meter and fit into the same all-in-one carrying device.
"Once we receive the proper regulatory clearances and approvals our Customer Support organization will help transition current users who move to the iPhone 7 and answer any questions new users may have about the product."
For more information on how DarioHealth is driving the mobile digital health market and how their product aims to be compatible with Apple's iPhone 7, please visit: www.mydario.com/iphone7-lightning/
Apple, iPhone and Lightning are registered trademarks of Apple Inc.
DarioHealth is a leader in digital health self-management solutions. DarioHealth delivers the ability to combine and analyze consumer health data to personalize treatment and advance medical knowledge. The Dario™ Blood Glucose Monitoring System is a platform for diabetes management that combines an all-in-one blood glucose meter, native smart phone app, website portal and a wide variety of treatment tools to support more proactive and better informed decisions by users living with diabetes, their doctors and healthcare systems. Having recently launched in the largest market in the world for glucose monitoring, U.S. sales are expected to have a significant impact on revenues and gross margins. With marketing clearance in Europe and the U.S., the Dario iOS mobile app recently launched with reimbursement in the United Kingdom, Australia, Israel, Italy, and Canada, and has also launched in New Zealand, Netherlands, Italy, and Belgium. For more information, visit: http://mydario.investorroom.com/
Cautionary Note Regarding Forward-Looking Statements
This press release and the statements of representatives and partners of DarioHealth Corp. (the "Company") related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. For example, the Company is using forward-looking statements in this press release when the Company describes its products' compatibility with the iPhone 7, regulatory approvals, and that U.S. sales are expected to have a significant impact on revenues and gross margins. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
DarioHealth Corporate and Media Contact
DarioHealth Investor Relations Contact
Rob Fink / Brett Maas
+1-646-415-8972 / +1-646-536-7331
SOURCE DarioHealth Corp.